Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estramustine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.86 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.86 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.86 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.86 |
| ▸ | DRD1 | P21728 | 1/20 | 0.86 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.86 |
| ▸ | KDR | P35968 | 1/20 | 0.86 |
| ▸ | RECQL | P46063 | 2/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estramustine Phosphate SCHEMBL13545664 | 0.93 | ESR1 (1.00) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine Phosphate SCHEMBL29379408 | 0.93 | ESR1 (1.00) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine Phosphate SCHEMBL234749 | 0.93 | ESR1 (1.00) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine Phosphate SCHEMBL1649356 | 0.93 | ESR1 (1.00) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine SCHEMBL19197890 | 0.90 | RECQL (0.92) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine SCHEMBL17350515 | 0.89 | RECQL (0.90) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine SCHEMBL3974 | 0.89 | RECQL (0.89) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine SCHEMBL7552087 | 0.89 | RECQL (0.89) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine SCHEMBL2534637 | 0.88 | RECQL (0.87) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine SCHEMBL9509552 | 0.87 | RECQL (0.89) | ESR1ADORA3PTPN11INPPL1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7527 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009778-A1 | KRAS ANTAGONISTS | TRUETIVA INC (US) | 2025-01-09 | — | — | US | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| WO-2024162488-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CUCURBITACIN D FOR PREVENTING OR TREATING NEUROPATHIC PAIN | 주식회사 재인알앤피 | 2024-08-08 | — | — | WO | claimed |
| EP-3664823-B1 | COMPOSITION FOR USE IN PREVENTING OR TREATING AN ENTEROCOCCAL BLOOD STREAM INFECTION | FINCH THERAPEUTICS HOLDINGS LLC (US) | 2024-06-05 | — | — | EP | claimed |
| WO-2024085332-A1 | ANTIBODY-BOUND METAL-ORGANIC FRAMEWORK AND ANTICANCER COMPOSITION COMPRISING SAME | 울산과학기술원 | 2024-04-25 | — | — | WO | claimed |
| EP-3243835-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-04-10 | — | — | EP | claimed |
| US-11952353-B2 | STAT3 transcription factor inhibitors and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2024-04-09 | — | — | US | claimed |
| US-20240066032-A1 | METHODS OF TREATING PROSTATE CANCER | ARVINAS OPERATIONS, INC. | 2024-02-29 | — | — | US | claimed |
| EP-3337816-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-02-14 | — | — | EP | claimed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| US-20010018919-A1 | Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response | DIMENSIONAL DOSING SYSTEMS, INCORPORATED | 2001-09-06 | — | — | US | claimed |
| WO-2000001419-A1 | DRUG COMPLEX FOR TREATMENT OF METASTATIC PROSTATE CANCER | JCRT RADIATION ONCOLOGY SUPPORT SERVICES, INC. (US) | 2000-01-13 | — | — | WO | claimed |
| EP-0875246-A1 | Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1998-11-04 | — | — | EP | claimed |
| EP-0856052-A1 | ANTISENSE OLIGONUCLEOTIDE CHEMOTHERAPY FOR BENIGN HYPERPLASIA OR CANCER OF THE PROSTATE | University of Massachusetts (US) | 1998-08-05 | — | — | EP | claimed |
| EP-0851919-A1 | ANTISENSE OLIGONUCLEOTIDE CHEMOTHERAPY FOR BENIGN HYPERPLASIA OR CANCER OF THE PROSTATE | University of Massachusetts Worcester (US) | 1998-07-08 | — | — | EP | claimed |
| WO-1997032589-A1 | COMBINATIONS FOR TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| WO-1997032604-A1 | ANTIPROLIFERATIVE COMBINATIONS, CONTAINING RAF-TARGETED OLIGONUCLEOTIDES AND CHEMOTHERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| WO-1997011172-A1 | ANTISENSE OLIGONUCLEOTIDE CHEMOTHERAPY FOR BENIGN HYPERPLASIA OR CANCER OF THE PROSTATE | UNIVERSITY OF MASSACHUSETTS (US) | 1997-03-27 | — | — | WO | claimed |
| WO-1997011170-A1 | ANTISENSE OLIGONUCLEOTIDE CHEMOTHERAPY FOR BENIGN HYPERPLASIA OR CANCER OF THE PROSTATE | WORCESTER FOUNDATION FOR BIOMEDICAL RESEARCH (US) | 1997-03-27 | — | — | WO | claimed |
| US-4584136-A | Process for preparing Estracyt compounds having a carcinostatic bound thereto | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1986-04-22 | — | — | US | claimed |